Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Peter Schmid, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Jaime Mejia, Xuan Zhou, Amin Haiderali, Allison Martin Nguyen, Javier Cortés, Eric P. Winer
Topics & Concepts
MedicinePembrolizumabNauseaVomitingQuality of life (healthcare)Clinical endpointInternal medicineChemotherapyOncologyBreast cancerCancerPhysical therapyRandomized controlled trialImmunotherapyNursingCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies